Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of urinary tract infection in children

Marmara Medical Journal

Volumn 16, Issue 2, 2003, Pages 107-112

  Bahar, Arif ^a   Karademir, Ferhan ^a   Unsur, Tolga ^a   Özyurt, Mustafa ^a   Göçmen, Ismail ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Amikacin; Aminoglycoside; Isepamicin; Pediatrics

Indexed keywords

AMIKACIN; CREATININE; ISEPAMICIN;

ARTICLE; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HEARING LOSS; HUMAN; INFANT; KLEBSIELLA PNEUMONIAE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAPHYLOCOCCUS; TINNITUS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO;

EID: 4043053640     PISSN: 10191941     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Krasinski KM. Urinary tract infections. In: Katz SL, Gershon AA, Hotez PJ. (eds) Krugman's Infectious Diseases of Children. 10th edition. St Louis, Missouri. Mosby Year Book, 1998: 606-619.
2. Wald ER. Cystitis and pyelonephritis. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Disease. 5th edition. Phyladelphia; Saunder, 2004: 541-553.
3. Johnson JG, Hardin TC. Aminoglycosides, imipenem, and aztreonam. Clin Pediatr Med Surg 1992; 9: 443-464.
4. Shimizu K, Kumada T, Hsieh W, et al. Comparison of aminoglycoside resistance patterns in Japan, Formosa and Korea, Chile and the United States. Antimicrob Agents Chemother 1985; 28: 282-288.
5. Sturm W. Isepamicin versus amikacin in the treatment of urinary tract infection. J Chemother 1995; 7: 149-154.
6. Vigano A, Principi N. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. J Chemother 1995; 7: 95-101.
7. Miller GH, Sabatelli FJ, Naples L, et al. The most frequently occuring aminoglycoside resistance mechanism-combined results of surveys in eight regions of the world. J Chemother 1995; 7: 17-30.
8. Gur D, Tutar I, Unlu GV, et al. Isepamisinin hastane izolati gram-negatif bakterilere karşi invitro etkisi. Hastane Inf Derg 2001; 5: 19-24.
9. Over U, Gur D, Unal S, et al. The changing nature of aminoglycoside resistance mechanism and prevalence of newly recognised resistance mechanism in Turkey. Clin Microbiol Infect 2001; 7: 470-478.
10. McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med 1986; 80: 172-178.
11. Scaglione F, Vigano A, Colucci R, et al. Pharmacokinetics of isepamicin in paediatric patients. J Chemother 1995; 7: 63-69.
12. Skaer TL. Dosing considerations in the pediatric patients. Clin Ther 1991; 13: 526-544.
13. Rodrigez-Noriega E, Esparza-Ahumada S, Morfin-Otero R. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. J Chemother 1995; 7: 155-160.
14. Tulkens PM. Nephrotoxicity of aminoglycosides. Toxicol Lett 1989; 46: 107-123.
15. Tulkens PM. Pharmacokinetic and toxicological evaluation of the once-a-day regimen versus conventional schedules of netilmicin and amikacin. Chemother 1991; 27: 49-61.
16. Tulkens PM, et al. Efficacy and safety of aminoglycosides once-a-day; Experimental and clinical data. Scand J Infect Dis 1990; 74: 249-257.